Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Kingobio Inc. is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to examiner DUNN, MCKENZIE A, who is the busiest examiner for the portfolio with 1 pending action. The prosecution footprint involves 1 distinct examiner and 1 distinct art unit.
The 1 pending office action represents the total current workload for the portfolio at the patent office. Because DUNN, MCKENZIE A is the 1 examiner involved, the prosecution strategy can be tailored to the specific requirements of this individual. The involvement of the Biotechnology & Pharmaceuticals area suggests the filings are subject to the specific examination guidelines of that field.
The data shows that 1 distinct art unit is responsible for the review of the pending matter. This concentration in the administrative division means the practitioner does not need to coordinate across different art units. The current profile reflects a prosecution state where the active matter is handled by DUNN, MCKENZIE A within the technical category. This allows for a specific approach to the pending office action without the need to manage different examiner preferences.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUNN, MCKENZIE A | 1 | 54.2% | +57.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18451734 | POLYMERIC MATERIAL-COATED NANOPARTICLE COMPLEX FOR ISOLATION OF BIOLOGICAL TARGET AND PREPARATION METHOD THEREFOR | DUNN, MCKENZIE A | — |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18451734 | POLYMERIC MATERIAL-COATED NANOPARTICLE COMPLEX FOR ISOLATION OF BIOLOGICAL TARGET AND PREPARATION METHOD THEREFOR | DUNN, MCKENZIE A | 1678 | §103 | Final Rejection | — | Pending | Aug 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKingobio Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Mckenzie A Dunn has the most, with 1 of Kingobio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
